Recombinant Human CD80/B7-1 Protein | PKSH031476

(No reviews yet) Write a Review
SKU:
575-PKSH031476
Weight:
1.00 KGS
€1,205.00
Frequently bought together:

Description

Recombinant Human CD80/B7-1 Protein | PKSH031476 | Gentaur US, UK & Europe Disrtribition

Synonyms: CD80; Activation B7-1 antigen; B7; BB1; CD28LG1; CD28LGB7-1 antigen; T-lymphocyte activation antigen CD80;B7-1;B7.1;CD28LG;LAB7

Active Protein: N/A

Activity: The mature form of human B7-1 (NP_005182.1) extracellular domain (Met 1-Asn 242) with five amini acids (DDDDK) at the C-terminus was expressed and purified.

Protein Construction: The mature form of human B7-1 (NP_005182.1) extracellular domain (Met 1-Asn 242) with five amini acids (DDDDK) at the C-terminus was expressed and purified.

Fusion Tag: N/A

Species: Human

Expressed Host: HEK293 Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 85 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per µg of the protein as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 25.5 kDa

Formulation: Lyophilized from sterile PBS, pH 7.4

Reconstitution: Please refer to the printed manual for detailed information.

Background: The B-lymphocyte activation antigen B7-1 (referred to as B7); also known as CD80; is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells; macrophages and dendritic cells. As costimulatory ligands; B7-1 which exists predominantly as dimer and the related protein B7-2; interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells; and thus constitute one of the dominant pathways that regulate T cell activation and tolerance; cytokine production; and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.Immune CheckpointImmune Checkpoint Detection: Antibodies   Immune Checkpoint Detection: ELISA Antibodies   Immune Checkpoint Detection: IHC Antibodies   Immune Checkpoint Detection: FCM Antibodies   Immune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint Targets   Co-inhibitory Immune Checkpoint Targets Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Research Area: immunology, Stem cells

View AllClose